Neon Therapeutics Inc (NASDAQ:NTGN)’s share price shot up 6.4% during trading on Friday . The stock traded as high as $1.01 and last traded at $1.00, 194,655 shares changed hands during trading. A decline of 30% from the average session volume of 277,613 shares. The stock had previously closed at $0.94.
Several brokerages recently weighed in on NTGN. Morgan Stanley cut Neon Therapeutics from an “overweight” rating to a “sell” rating in a research report on Tuesday, November 26th. Mizuho lowered their price objective on Neon Therapeutics from $21.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. HC Wainwright cut shares of Neon Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 27th. Zacks Investment Research lowered shares of Neon Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 29th. Finally, Bank of America cut shares of Neon Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the stock. Neon Therapeutics presently has an average rating of “Hold” and a consensus price target of $10.58.
The firm’s 50 day moving average price is $1.70 and its 200-day moving average price is $3.02. The company has a debt-to-equity ratio of 0.15, a quick ratio of 4.59 and a current ratio of 4.59.
In other Neon Therapeutics news, insider Richard Gaynor sold 22,322 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $1.24, for a total transaction of $27,679.28. Following the transaction, the insider now owns 201,822 shares in the company, valued at $250,259.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 38.93% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in NTGN. BlackRock Inc. increased its holdings in Neon Therapeutics by 11.6% in the 2nd quarter. BlackRock Inc. now owns 765,850 shares of the company’s stock worth $3,631,000 after acquiring an additional 79,729 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Neon Therapeutics by 3.6% during the second quarter. Vanguard Group Inc. now owns 612,398 shares of the company’s stock valued at $2,903,000 after purchasing an additional 21,387 shares in the last quarter. State Street Corp lifted its holdings in Neon Therapeutics by 14.7% during the third quarter. State Street Corp now owns 221,268 shares of the company’s stock valued at $381,000 after purchasing an additional 28,334 shares in the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of Neon Therapeutics in the third quarter valued at about $361,000. Finally, Northern Trust Corp grew its position in shares of Neon Therapeutics by 8.5% in the second quarter. Northern Trust Corp now owns 166,467 shares of the company’s stock valued at $789,000 after purchasing an additional 12,971 shares during the period. 58.19% of the stock is currently owned by hedge funds and other institutional investors.
Neon Therapeutics Company Profile (NASDAQ:NTGN)
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
Featured Article: How can investors benefit from after-hours trading?
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.